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Background and aims: Developing sparse panels of biomarkers for cardiovascular disease in type 2
diabetes would enable risk stratiﬁcation for clinical decision making and selection into clinical trials. We
examined the individual and joint performance of ﬁve candidate biomarkers for incident cardiovascular
disease (CVD) in type 2 diabetes that an earlier discovery study had yielded.
Methods: Apolipoprotein CIII (apoCIII), N-terminal prohormone B-type natriuretic peptide (NT-proBNP),
high sensitivity Troponin T (hsTnT), Interleukin-6, and Interleukin-15 were measured in baseline serum
samples from the Collaborative Atorvastatin Diabetes trial (CARDS) of atorvastatin versus placebo. Among
2105 persons with type 2 diabetes and median age of 62.9 years (range 39.2e77.3), there were 144
incident CVD (acute coronary heart disease or stroke) cases during the maximum 5-year follow up. We
used Cox Proportional Hazards models to identify biomarkers associated with incident CVD and the area
under the receiver operating characteristic curves (AUROC) to assess overall model prediction.
Results: Three of the biomarkers were singly associated with incident CVD independently of other risk
factors; NT-proBNP (Hazard Ratio per standardised unit 2.02, 95% Conﬁdence Interval [CI] 1.63, 2.50),
apoCIII (1.34, 95% CI 1.12, 1.60) and hsTnT (1.40, 95% CI 1.16, 1.69). When combined in a single model, only
NT-proBNP and apoCIII were independent predictors of CVD, together increasing the AUROC using
Framingham risk variables from 0.661 to 0.745.
Conclusions: The biomarkers NT-proBNP and apoCIII substantially increment the prediction of CVD in
type 2 diabetes beyond that obtained with the variables used in the Framingham risk score.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Informatics and Life Course
r Medicine, Western General
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Cardiovascular disease (CVD) remains a major cause of
morbidity and mortality among people with type 2 diabetes (T2D).
Currently risk equations such as Framingham are the most
commonly used method for assessing an individual's CVD risk [1]
though other diabetes speciﬁc models have also been shown to
have beneﬁt [2]. One potential means to further improve predictionnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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combination with established clinical risk factors. Among bio-
markers shown to be most predictive of CVD in T2D are N-Terminal
Prohormone B-type Natriuretic Peptide (NT-proBNP) and high-
sensitivity Troponin T (hsTnT) [3]. Recent data also support the
potential of Apolipoprotein CIII (apoCIII) as a predictive biomarker
in the context of higher triglycerides such as T2D, though whether
apoCIII predicts CVD independently of triglycerides in diabetes is
unclear [4e6].
Most biomarker studies have tended to focus on single
biomarker evaluation, while joint evaluation of panels of bio-
markers are relatively uncommon [7,8]. In a previous biomarker
discovery study across ﬁve cohorts with diabetes that evaluated 42
biomarkers, we identiﬁed a subset of biomarkers that together
improved prediction for incident CVD events in T2D. These
included NT-proBNP, hsTnT, Interleukin-6 (IL-6) and Interleukin-15
(IL-15)- all of which were positively associated with CVD. ApoCIII
showed a weak inverse association with CVD, at odds with the
direction of effect expected from its known biology [7]. In an
assessment of a large panel of potential biomarkers in people with
dysglycaemia in the ORIGIN trial, NT-proBNP was also the most
predictive biomarker with 10 additional biomarkers and, in a later
analysis, Troponin I showed additional predictive information [9].
Here we used samples from the Collaborative Atorvastatin
Diabetes Study (CARDS) clinical trial of atorvastatin versus placebo
for the primary prevention of CVD in T2D10 to quantify the extent to
which prediction of CVD can be improved with NT-proBNP, hsTnT,
IL-6 and IL-15, and with apoCIII beyond that obtained with the
variables used in the Framingham risk score and also a wider set of
potential clinical risk factors.
2. Materials and methods
2.1. Populations
As previously detailed, CARDS (ClinicalTrial.gov registration no.
NCT00327418) was a clinical trial of the effects of Atorvastatin in
T2D and included adults aged 40e75 years with T2D recruited from
across the UK and Irelandwith no pre-existing CVD, but at least one
CVD risk factor (e.g. smoking, hypertension, albuminuria, or reti-
nopathy) [11]. Patients were randomised between November 1997
and June 2001 and followed up 4 and 3.9 years in the active and
placebo arms respectively. Of the 2838 people originally included in
CARDS we had serum available, from a pre-randomisation visit, for
2105 people. There was no difference in incident CVD rate between
those with and without available serum samples. The study was
carried out in accordance with the Declaration of Helsinki and the
guidelines on Good Clinical Practice, with each centre obtaining
Local Research Ethics Committee approval following approval from
the Multi-centre Research Ethics Committee. All patients gave fully
informed written consent.
2.2. Clinical covariates
Clinical covariates were collected at the time of study enrolment
and included standard CVD risk factors including fasting total, low-
density (LDL-C) and high-density (HDL-C) cholesterol, triglycerides,
blood pressure, smoking status, and use of anti-hypertensive drugs
along with diabetes speciﬁc risk factors such as diabetes duration,
HbA1c, serum creatinine, albumin:creatinine ratio (ACR) and insulin
use. Estimated glomerular ﬁltration rate (eGFR) was calculated
using the MDRD4 equation [11] and albuminuria status was based
on ACR at study enrolment with microalbuminuria deﬁned as an
ACR 2.5e25mg/mmol, and macroalbuminuria as an ACR> 25mg/
mmol [10].2.3. Endpoint deﬁnition
Incident CVD in CARDS participants was as deﬁned in the
original triale acute coronary heart disease (a documented
myocardial infarction including silent myocardial infarctions
detected by electrocardiography, unstable angina, revascularisation
or acute coronary heart disease death) or fatal and non-fatal stroke.
We also examined associations of the biomarkers with four sec-
ondary endpoints: fatal CVD, non-fatal CVD, acute coronary heart
disease, and stroke. These outcomes are in line with the ASSIGN
CVD event deﬁnitions used in the development of risk scores [12].
2.4. Biomarker measurements
Biomarker measurements were made on thawed serum in
several batches (see Supplementary Table 1 for quality control
data). Three of the biomarkers (apoCIII, IL-6 and IL-15) were
measured at the Immunoassay Biomarker Core Laboratory at the
University of Dundee, Scotland. For apoCIII. we used the Assaymax
ELISA from Assaypro. For the Interleukins we used the V-PLEX
Human Interleukin-6 Kit [13] and the V-PLEX Human Interleukin-
15 Kit [14] both from Meso Scale Discovery [15]. NT-proBNP and
hsTNT were measured at the Glasgow Biomarker Laboratory, Uni-
versity of Glasgow, Scotland, in a sub-set of samples selected to
include all events (n¼ 113), where sufﬁcient sample volume was
available to account for dead volume in automated analysers, and a
random selection of samples from among those without an event
(n¼ 1456). NT-proBNP was measured with the Elecsys proBNP II
assay [16] and hsTnT [17] with the Elecsys Troponin T high sensi-
tivity assay both from Roche Diagnostics (Burgess Hill, UK). For all
assays a small number of blinded duplicates were included to
assess the intra-class correlation coefﬁcients (ICCs). In addition to
the biomarkers measured, we also include measures of C-reactive
protein and apolipoprotein B (apoB) concentrations previously
measured in CARDS [18,19] as covariates in some analyses.
2.5. Statistical analysis
The data were cleaned, imputed and Gaussianised prior to
analysis. Four missing covariate values were imputed to the mean
for continuous variables and to the mode for categorical variables.
We did not impute the 87 missing ACR observations, but instead
ran a sub-analysis when this covariate was included in the model
(n¼ 2018, 138 incident CVD events). Biomarker values missing at
randomwere imputed to the mean (n¼ 32) but we conﬁrmed that
similar results were obtained with these observations dropped
from the analyses. We used Cox Proportional Hazards models to
assess the association of each biomarker singly and in combination
over and above a limited set of clinical covariates based upon the
Framingham risk equation (age, sex, total cholesterol, HDL-C, sys-
tolic blood pressure and smoking status) and also a wider set of
potential predictive clinical covariates. All analyses also adjusted
for treatment assignation in the trial. We report the Hazard Ratio
(HR) per unit standard deviation of each biomarker when Gaus-
sianised. We also tested for departure from linearity by examining
whether including a quadratic term in the models improved model
ﬁt, as assessed by a likelihood ratio test. Since many people had no
detectable levels of hsTnT, we tested whether modelling it using a
term of undetectable, below, and above, median yielded better
prediction than treating it as a continuous variable where samples
below the detection level were set to 50% of the detection
threshold. For IL-6, since raw data plotted into quartiles suggested a
threshold effect above the ﬁrst quartile, we conducted a post-hoc
test of signiﬁcance of being above the ﬁrst quartile overall with CVD
risk. Such post-hoc analyses are of course suggestive rather than
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To assess the overall predictive power of the models we used 10
fold cross-validation to calculate the Somers' D statistic (D) from
which we calculated the area under the Receiver Operator Char-
acteristic curves (AUROC) using the formula AUROC ¼ 0.5 þ 0.5*D.
We carried out a series of sensitivity analyses. In one we re-ran all
models after excluding eight individuals with very high baseline
NT-proBNP (>400 pg/ml). We also re-ran the apoCIII models
substituting LDL-C with serum apoB, a marker for the number of
LDL particles in the circulation and a predictor of CVD in CARDS
[20]. We also calculated the positive predictive value of the test
where the probability of being a CVD case is plotted against the
percentile of the risk score derived from a logistic regression model
inclusive of biomarkers. We did this to demonstrate how using
different cut points of the model score to enrich CVD incidence
among potential clinical trial enrollees similar to the CARDS pop-
ulation might alter probability of identifying those at risk for CVD
i.e. the “predicted event rate enrichment”. All statistical analyses
were undertaken using R [21].
3. Results
Serum samples were available for 2105 individuals from CARDS
of whom 144 had an incident ﬁrst CVD event during follow-up. Of
the 144 events 51% were due to myocardial infarction, 25% due to
stroke, 13% revascularisation procedures, 7% due to unstable angina
and 4% due to other acute coronary heart disease death. De-
mographics and baseline clinical covariates by subsequent CVD
event status are shown in Table 1. Individuals with incident CVD
events during the study were older, more likely to be male, with a
higher BMI, higher total and LDL-C and with macroalbuminuria at
study enrolment. Treatment assignment to statin was associated
with reduced CVD events as described and treatment assignment
was adjusted for in all models. The median time to incident CVD
event was 2.1 years (Interquartile range [IQR] 1.0, 3.4 years) and for
people who did not have an incident event, median follow-up was
4.1 years (IQR 3.3, 4.7 years).
3.1. Biomarker associations with CVD
For apoCIII, IL-6, IL-15 and NT-proBNP, > 98% of samples had
detectable levels but as expected just 43% of samples assayed for
hsTnT had detectable levels. On blinded duplicate aliquots ICCs
were good for all assays (Supplementary Table 1). Correlations of
biomarkers with each other and with clinical covariates are shown
in Supplementary Fig. 1. The strongest correlations seen were for
apoCIII with triglycerides (r¼ 0.41) and NT-proBNP with age (0.36).
The biomarkers did not show much correlation with each other
except for hsTnT and NT-proBNP (r¼ 0.30). IL-6 was modestly
correlated with CRP (r¼ 0.29). Biomarkers were not associated
with HbA1c. NT-proBNP was higher with lower eGFR.
HRs for each biomarker when added to models including either
the Framingham covariates or the more extensive set of covariates
are shown in Table 2. Modelled as continuous terms, three of the
biomarkers were statistically signiﬁcantly associated with incident
CVD; apoCIII, NT-proBNP and hsTnT-while we found no signiﬁcant
association for IL-6 or IL-15. Inclusion of a quadratic term in the
model did not signiﬁcantly improve model ﬁt (data not shown).
Associations were robust to both adjusting for Framingham cova-
riates and the more extensive set of covariates including tri-
glycerides. However, when all three biomarkers associated in
univariate analysis (apoCIII, NT-proBNP and hsTnT) were included
in a model simultaneously, hsTnT was no longer independently
associated with CVD (Table 2).
Although there was no signiﬁcant linear association between IL-6 and CVD, there was some evidence (Table 1) from post-hoc ana-
lyses that CVD risk was higher in those above the 1st quartile for IL-
6 compared to those in the 1st quartile (HR¼ 1.82; 95% CI 1.13, 2.93;
p¼ 0.013 adjusted for extensive covariates). Modelling hsTnT as a
categorical variable revealed a very strong association between
CVD risk and having values above the median (6.51 pg/ml)
compared to having undetectable values (HR 2.36; 95% CI 1.52,
3.67; p¼ 0.0001 adjusted for extensive covariates). However, even
when treated as these categorical variables, neither IL-6 nor hsTnT
were associated with CVD in a model that included apoCIII and NT-
proBNP.
3.2. Prediction performance
In terms of predictive performance for CVD (using AUROCs from
a 10 fold cross-validation), the AUROC increased from 0.661 for
Framingham covariates alone to 0.729 when including NT-proBNP
alone and to 0.676 when including apoCIII alone. The inclusion of
both apoCIII and NT-proBNP increased the AUROC from 0.661 (95%
CI% 0.615e0.706) to 0.745 (95% CI: 0.701e0.789), a difference that
was highly statistically signiﬁcant (p¼ 0.0005). (Fig. 1A). The
AUROC for CVD increased from 0.652 for extensive covariates alone,
to 0.732 with the inclusion of apoCIII and NT-proBNP (Fig. 1B).
A useful metric beyond AUROC that summarizes the potential
value of biomarkers in selection of patients for a clinical trial is the
‘predicted event rate enrichment’ achieved by using the biomarkers
in a given potential clinical trial population (Fig. 2). This corre-
sponds to the positive predicted value (PPV) computed over a
growing proportion of patients, from only the patients most at risk
(left side of the plot) to all individuals in the study (right side of the
plot). For example, in the subsample from CARDS used in this study,
the cumulative incidence of CVD was 6.8%. Thus, without any se-
lection by risk stratiﬁcation, the expected cumulative incidence of
CVD is 6.8% (y-axis value when x¼ 100%). The plot illustrates that
by selecting, say, the most extreme 20% of patients based on their
score from a model using the Framingham covariates (red line)
would enrich the cumulative incidence of CVD to 11%. At the same
20% threshold, using a model based on Framingham covariates and
selected biomarkers (blue line) would enrich the cumulative inci-
dence of CVD to 16%. This illustrates that even small increments in
AUROC can yield useful enrichment for events when the extremes
of risks scores that include biomarkers are selected.
3.3. Sensitivity analyses
NT-proBNP is strongly associated with heart failure. While all
participants were free of CVD at baseline, we undertook a sensi-
tivity analysis excluding all 8 individuals with an NT-proBNP
>400 pg/ml at baseline (n¼ 1501 with 105 incident cases of CVD).
There was little difference in the association of NT-proBNP with
CVD with these 8 patients excluded (HR¼ 2.01; 95% CI 1.56, 2.58).
The sub-analyses restricted to those in whom albuminuria status
was also available (n¼ 2018, 138 incident CVD events) made little
difference to the univariate biomarker associations (apoCIII HR
1.36; 95% CI 1.13, 1.64; NT-proBNP HR 1.99; 95% CI 1.59, 2.49; and
hsTnT HR 1.40; 95% CI 1.16, 1.69). Substituting apoB for LDL-C in the
models did not appreciably change the associations between bio-
markers and CVD (data not shown).
3.4. Secondary end-point analyses
We examined the association of apoCIII and NT-proBNP with
fatal and non-fatal events and with stroke and coronary heart
disease (CHD) separately. In the model containing both these bio-
markers, for apoCIII the HRs per Gaussianized SD were similar for
Table 1
Baseline demographics and biomarker concentrations of CARDS study participants by incident CVD status (n¼ 2105).
No CVD event (n¼ 1961) CVD event (n¼ 144) p-value adjusted
for age and sex
Median/frequency Interquartile range Median/frequency Interquartile range
Age (years) 62.7 55.7, 67.9 65.0 61.1, 69.4 <0.001a
Male sex 66.3% e 85.4% e <0.001b
Diabetes duration (years) 6.0 3.0, 11.0 7.5 3.0, 12.0 0.267
Systolic blood pressure (mmHg) 143 134, 153 145 135, 155 0.743
Diastolic blood pressure (mmHg) 83 77, 89 84 79, 87 0.598
Height (m) 1.71 1.63, 1.77 1.72 1.65, 1.77 0.011
BMI (kg/m2) 28.7 26.1, 31.4 29.0 27.1, 31.0 0.032
HbA1c (%) [mmol/mol] 7.7 [60.6] 6.8, 8.7 [50.8, 71.6] 7.6 [59.6] 6.9, 8.4 [51.9, 68.3] 0.768
eGFR (ml/min/1.73m2) 64.2 57.3, 71.0 64.6 57.4, 70.5 0.403
Total cholesterol (mmol/l) 5.4 4.8, 5.9 5.5 4.9, 6.0 0.007
LDL cholesterol (mmol/l) 3.05 2.56, 3.55 3.11 2.69, 3.68 0.007
HDL cholesterol (mmol/l) 1.36 1.17, 1.57 1.35 1.19, 1.52 0.584
Triglycerides (mmol/l) 1.67 1.17, 2.37 1.70 1.20, 2.55 0.456
Smoking status
Never 34.7% e 30.6% e e
Ex 43.6% e 41.7% e 0.214
Current 21.7% e 27.8% e 0.171
Insulin therapy 19.7% e 18.8% e 0.966
Aspirin use 14.9% e 18.1% e 0.604
Antihypertensive use 66.8% e 63.9% e 0.428
Lipid lowering drug use 0.2% 0.7% 0.134
Randomised to atorvastatin 52.2% e 41.7% e 0.016
Albuminuria status c
Normoalbuminuric 73.2% e 62.3% e e
Microalbuminuric 22.8% e 29.0% e 0.150
Macroalbuminuric 4.0% e 8.7% e 0.013
Apolipoprotein CIII (mg/ml) 96.4 47.4, 179.1 119.4 56.4, 197.7 0.005
Interleukin-6 (pg/ml) 0.40 0.25, 0.68 0.44 0.32, 0.81 0.261
Interleukin-6 (categorical)
Quartile 1 (0.25 pg/ml) 26.1% e 14.6% e e
Quartiles 2, 3, 4 73.9% e 85.4% 0.006
Interleukin-15 (ng/ml) 0.83 0.62, 1.12 0.84 0.57, 1.16 0.541
N-terminal prohormone B-type natriuretic peptide (pg/ml) d 43.2 25.4, 85.6 85.7 42.7, 160.7 <0.001
High sensitivity Troponin T (pg/ml) d 1.5 1.5, 5.5 4.1 1.5, 9.1 0.004
High sensitivity Troponin T (categorical)d
Below detection 58.1% e 40.4% e e
Below median 21.6% e 18.4% e 0.819
Above median 20.3% e 41.2% e 0.002
a Adjusted for sex only.
b Adjusted for age only.
c Data available for 2018 people (133 cases).
d Data available for 1569 subjects (114 cases).
Table 2
Hazard ratios per standardised unit of biomarkers for incident CVD adjusted for clinical covariates.
Adjusted for Framingham covariatesa Adjusted for full covariatesb
Hazard ratio 95% Conﬁdence interval p-value Hazard ratio 95% Conﬁdence interval p-value
Biomarkers assessed singly
ApoCIII 1.29 1.09, 1.53 0.004 1.34 1.12, 1.60 0.002
Interleukin-6 1.07 0.92, 1.24 0.377 1.07 0.91, 1.25 0.433
Interleukin-15 1.06 0.89, 1.25 0.520 1.05 0.89, 1.24 0.584
N-terminal prohormone B-type natriuretic peptide 1.89 1.54, 2.32 <0.0001 2.02 1.63, 2.50 <0.0001
High sensitivity Troponin T 1.40 1.17, 1.69 0.0003 1.40 1.16, 1.69 0.0004
Biomarkers assessed together
ApoCIII 1.49 1.23, 1.81 <0.0001 1.55 1.26, 1.90 <0.0001
N-Terminal prohormone B-type natriuretic peptide 1.82 1.46, 2.27 <0.0001 1.94 1.54, 2.45 <0.0001
High sensitivity Troponin T 1.15 0.94, 1.39 0.169 1.10 0.90, 1.33 0.348
a Framingham covariates include age, sex, systolic blood pressure, total cholesterol, HDL cholesterol, smoking status and randomisation arm.
b Full covariates include the Framingham set plus BMI, triglycerides, LDL cholesterol, diastolic blood pressure, HbA1c, diabetes duration, eGFR, height, insulin use and
antihypertensive use (including subgroups of antihypertensive agents).
M. Colombo et al. / Atherosclerosis 274 (2018) 182e190 185fatal (HR 1.53 (1.03, 2.26)) and non-fatal events (HR 1.50 (1.21,1.87))
and were similar for stroke (HR 1.45 (0.99, 2.13)) and CHD (HR 1.53
(1.22, 1.91)). For NT-proBNP, the HR for fatal events (3.03 (1.95,
4.70)) was somewhat larger than for non-fatal events (1.68 (1.33,2.13)) and was larger for CHD (2.29 (1.80, 2.91)) than for stroke (1.18
(0.78, 1.77)), though conﬁdence limits were wide examining these
subsets of events.
Fig. 1. ROC curves.
(A) Models adjusted for the Framingham clinical covariates, (B) models adjusted for an extensive set of clinical covariates.
Fig. 2. Expected cumulative event rate.
The ﬁgure shows how the expected cumulative event rate would increase from the observed 6.8% (horizontal line) if the trial subsampled the percentage of possible study entrants
with a risk score above a given threshold (as denoted on the x-axis) for (i) risk score based on Framingham score variables (in red) and (ii) risk score also including the biomarkers
(in blue).
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We have shown that serum apoCIII increments prediction of
CVD in type 2 diabetes on top of serumNT-proBNP and an extensive
set of clinical risk factors including triglycerides, and factors
important in diabetes such as diabetes duration, HbA1c and renal
function [20,22]. By selecting those at the extreme of a risk score
that includes clinical covariates apoCIII and NT-proBNP, useful
enrichment of clinical trial participants for CVD events could be
obtained.
Despite the development and ongoing clinical trial assessment
of apoCIII-directed therapies, relatively few studies have examined
circulating levels of serum or plasma apoCIII as a predictor of CVD.
In our study we used the Assaymax ELISA from Assaypro and we
demonstrated an association of serum apoCIII with CVD that was
independent of triglyceride levels. A previous meta-analysis of the
six prospective or retrospective studies available at that time found
that total plasma apoCIII was associated with a pooled average
relative risks of 1.33 for incident CVD for an increase in apoCIII of
5mg/dL [5]. However, of the prospective cohort or nested case
control studies [23], only one showed an association that was in-
dependent of triglycerides; in the Hoorn study, plasma apoCIII
measured using an immunoturbidimetric assay (Daiichi) on a Cobas
Mira analyzer (ABX Diagnostics) predicted CVD mortality inde-
pendently of other covariates including triglycerides which were
not themselves associated with CVDmortality [24]. Recently, in the
EPIC-Norfolk prospective cohort study using an in-house chemi-
luminescent enzyme-linked immunoassay, plasma apoCIII levels
were associated within incident coronary artery disease (CAD) but
this was not independent of triglyceride level. Correlations be-
tween apoCIII and triglyceride were very similar in that study
(r¼ 0.39) to ours (r¼ 0.49). However, in the EPIC-Norfolk cohort
very few had overt diabetes and also higher triglycerides were
associated with CAD. In contrast all our participants had T2D but
among these triglycerides were not strongly associated with CVD. It
is possible that in largely non-diabetic cohorts triglycerides predict
CAD in part because they are associatedwith dysglycaemia and pre-
diabetes [25], but that such associations are attenuated when all
participants already have diabetes. So whilst both these studies
provide supportive evidence for apoCIII as a target of therapy for
CVD, the usefulness of apoCIII as a predictive biomarker is only
supported by our study. Whether apoCIII is useful for prediction of
CVD in diabetes beyond extensive clinical covariate data and other
strong biomarkers such as NT-proBNP has not been unequivocally
shown previously. We previously reported an unexpected weak
inverse association between serum apoCIII and incident CVD in
diabetes patients [7]. In that study we drew attention to the un-
expected direction of effect. In that study we used the same assay
but a different laboratory; the inter-run CV for the assay was double
what we assessed in this study (15%, as opposed to 7.3% in this
study) and the levels were several fold higher, which may explain
the discrepant ﬁndings. Of note, the ORIGIN trial, which is one of
the few studies to have measured a large number of biomarkers
simultaneously, did measure both NT-proBNP and apoCIII using
Luminex technology. However, apoCIII was not one of the leading
biomarkers selected in their univariate analyses. The inter-run CV
reported for apoCIII in that study was higher than in ours at 20% [8].
We note that their analysis did not adjust for any measure of eGFR
which may also have inﬂuenced which biomarkers are selected
ﬁrst.
ApoCIII is primarily a constituent of triglyceride rich lipopro-
teins such as Very Low Density Lipoprotein (VLDL) with strong
biological evidence for a role in the pathophysiology of CVD. A null
mutation of the apoCIII gene is associated with low triglycerides,
low LDL-C and high HDL-C along with lower prevalence of CVD[26]. There is considerable interest in apoCIII, not only as a potential
biomarker for CVD risk, but also as a potential therapeutic target for
preventing CVD [27]. The mechanisms bywhich apoCIII affects CVD
are not fully understood but several pathways may be relevant. In
particular, in-vitro studies show apoCIII inhibits lipoprotein lipase
leading to hypertriglyceridemia [28] and inhibits hepatic clearance
of lipid remnants by disrupting the interaction of apoE with the
LDL-C receptor [29]. In some studies despite no association of total
apoCIII with CAD, the ratio of total plasma apoCIII to HDL was
shown to be higher in CAD patients than controls and inversely
correlated with cholesterol efﬂux capacity [30]. In other studies
HDL containing apoCIII was positively associated with CAD risk
[31]. Recently the co-existence of apoCIII on HDL with apoE on HDL
has also been shown to attenuate the beneﬁcial effect of apoE on
reverse cholesterol transport [32].
ApoCIII also has a pro-inﬂammatory role as it increases the
expression of pro-inﬂammatory adhesion molecules in endothelial
cells via the activation of nuclear factor-kappaB and protein kinase
C [33]. High apoCIII also increases the susceptibility of LDL-C to
hydrolysis and increases the accumulation of lipids in vessel walls.
These pro-inﬂammatory properties require sialyation of apoCIII and
this process increases with increased LDL-C apoCIII content [4]. The
Epic-Norfolk mediation analysis concluded that much of the CAD
risk associated with apoCIII could be attributed to higher levels of
triglyceride rich remnant particle concentrations but also by higher
LDL particle concentrations.
NT-proBNP has repeatedly been shown to be predictive of CVD
[34e36] and more recently it was the leading biomarker identiﬁed
as a predictor of incident CVD in diabetes in the ORIGIN trial [8]. The
cleaving of prohormone BNP separates the active hormone, BNP,
from the inactive fragment NT-proBNP. Both are measurable in
blood and recognised as biomarkers for heart failure [37]. We had
previously identiﬁed NT-proBNP as the single strongest biomarker
of incident CVD in a case-control study including individuals with
diabetes from ﬁve European cohorts and we have conﬁrmed that
ﬁnding here in this independent sample set [35]. An important
consideration in diabetes is whether such associations are
confounded by reduced eGFR, an important risk factor for CVD but
which is also associated with elevated NT-proBNP. No adjustment
for eGFR was made in the ORIGIN analysis but herewe showed that
the HR for CVD associated with NT-proBNP was little changed by
adjusting for eGFR. Neither was the association driven by the in-
clusion of individuals with subclinical incipient heart failure as we
obtained very similar results after excluding individuals with
elevated NT-proBNP at baseline and since overt heart failure was an
exclusion criterion in CARDS. The data are also consistent with
reports from theWest of Scotland Study Coronary Prevention Study
(WOSCOPS) which showed that NT-proBNP is more strongly asso-
ciated with fatal CVD than non-fatal CVD [38]. NT-proBNP levels
have been shown to predict CAD events beyond coronary artery
calcium score in the general population [39], though not in those
with diabetes [40]. ApoCIII has not been assessed in this context.
Troponin T is produced in cardiac muscle cells and is already
used as a biomarker of acute myocardial infarction [41]. The
introduction of high sensitivity assays opened the possibility of
hsTnT being used as a biomarker for non-acute CVD risk [42]. The
combination of NT-proBNP and hsTnT improved risk prediction for
CVD among people with T2D in the Atherosclerosis Risk in Com-
munities study [43] and in a nested case cohort from the ADVANCE
trial where the combination of biomarkers also predicted all-cause
mortality [44]. NT-proBNP and hsTnT also improved prediction of
CVD in the Multi-Ethnic Study of Atherosclerosis, a study not
restricted to people with diabetes; however, the improvement due
to hsTnT was small [35]. In our study with adjustment for NT-
proBNP (which is correlated with hsTnT) no useful additional
M. Colombo et al. / Atherosclerosis 274 (2018) 182e190188increment in prediction of CVD was obtained with hsTnT.
We did not ﬁnd any linear associations between either IL-6 or IL-
15 and incident CVD in this study. We selected these as candidate
biomarkers based on our previous biomarker discovery study
across ﬁve cohorts with T2D in which we found they were pre-
dictive of CVD. Previous studies have identiﬁed IL-6 as a risk factor
for non-fatal CVD [45], CVD mortality [45,46] and all-cause mor-
tality [46,47] in people with T2D. However, overall concentrations
of IL-6 in CARDS were lower compared to previous studies which
found evidence of a positive association with incident CVD
[7,45e47]. Consistent with the results for IL-6 and IL-15 a prior
study in CARDS did not ﬁnd any signiﬁcant association with CRP
and incident CVD either [18]. This may reﬂect the younger age of
CARDS study population than in some of the previous studies and
the strong selection for no prior evidence of any CVD.
Strengths of the current study are that it makes use of samples
from a clinical trial with all samples drawn in accordancewith clear
protocols, and as CVD was the primary end-point of the study all
cases had been reviewed and adjudicated according to the trial
protocol reducing the risk of misclassiﬁcation [48]. We measured
the biomarkers for this study using commercially available assays
which met high QC standards and for three of them, we were able
to use identical assays to those used in the earlier SUMMIT CVD
study. Limitations of the study are that it is a relatively small sample
size, with only 144 cases and a follow-up of under 5 years. This
means we cannot make any inferences about the performance of
these biomarkers over a longer period such as the more traditional
ten years. Moreover, we are underpowered to deﬁnitively test
whether associations differ with fatal versus non-fatal events or
with stroke versus CHD, with data suggesting that the best
biomarker for stroke, say, may well not be the best biomarker for
CHD. The study population is also principally Caucasian, limiting us
from any assessment of the biomarkers in other ethnicities.
Statistical signiﬁcance of AUROC improvement and clinical sig-
niﬁcance of such improvement are not the same thing. Whether or
not any given increment in AUROC is useful depends on the
context; speciﬁcally it depends on the prior probability of disease,
what posterior probability of disease one wishes to classify a pa-
tient as having in order to reach a given clinical decision, and
therefore the threshold value of the likelihood ratio generated by
the test needed to achieve this posterior probability. This likelihood
ratio is obtained from the ROC curve. We have illustrated that the
improvement with NT-proBNP and apoCIII gained here would be
useful in stratiﬁcation into clinical trials if those with extreme
values of the biomarkers were selected for inclusion. In terms of
clinical decision making, for illustration in the CARDS cohort the
observed rate of CVD over the median follow up of 3.7 years was
6.8%. If say in a cohort of patients with a similar overall event rate
(i.e. prior probability of disease) one wanted to identify the subset
of individuals with a risk of at least 20% over 10 years, this would
require any test result threshold to have a likelihood ratio of 3 for
favouring case over control status. At this cut-off it can be shown
the model including the biomarkers would have twice the sensi-
tivity of the Framinghammodel alone at a slightly lower speciﬁcity.
In conclusion, we ﬁnd evidence that both NT-proBNP and
apoCIII may have use in improving prediction of incident CVD in
individuals with T2D and no evidence of existing CVD. Even when
using all available clinical risk factor data including measures of
diabetes control and renal function, these biomarkers were asso-
ciated with an improvement in prediction. The PONTIAC trial
showed that risk stratiﬁcation into trials using NT-proBNP was
useful in identifying high-risk patients with diabetes for intensive
primary prevention trial for CVD [49]. Here we provide data sug-
gesting that, combined with NT-proBNP, apoCIII can also be useful
in clinical trial event rate enrichment in diabetes.Conﬂicts of interest
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